May 13, 2015Open Access

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Robert J. Mayer

Eric Van Cutsem

Alfredo Falcone

Journals

New England Journal of Medicine

Actions

Institutions

Harvard University

University of Southern California

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study